Med-X, Inc. filed Amendment No. 5 to its Form S-1 registration statement on November 19, 2026, seeking to register up to 16,248,842 post-split shares of common stock for resale in connection with a planned direct listing on the Nasdaq Global Market.
Key Highlights
- Shares registered: Up to 16,248,842 post-split shares of common stock are being registered for resale by existing stockholders.
- Direct listing structure: The offering is structured as a direct listing, not a firm-commitment underwritten initial public offering; no investment bank is underwriting the resale.
- No proceeds to company: According to the filing, Med-X will not receive any proceeds from the sale of shares by the Registered Stockholders.
- Historical capital raised: From inception on February 14, 2014, through October 14, 2026, the company raised approximately $38,081,204 in net proceeds from stock sales at an average post-split price of $2.89 per share.
- Financial advisor: Maxim Group LLC has been engaged as financial advisor to assist with matters relating to the direct listing.
- Nasdaq listing application: The company has applied to list its common stock on the Nasdaq Global Market under the equity standard; the filing states there can be no assurance the application will be approved.
- Company classification: Med-X is identified in the filing as a non-accelerated filer, smaller reporting company, and emerging growth company.
Med-X Seeks Nasdaq Direct Listing Through Resale Registration
Med-X, Inc., a Nevada-incorporated company headquartered at 8236 Remmet Avenue, Canoga Park, California, filed Amendment No. 5 (Registration No. 333-299158) to its S-1 registration statement under the Securities Act of 1933. The filing covers the proposed resale of up to 16,248,842 post-split shares of common stock by stockholders identified in the prospectus as "Registered Stockholders," in connection with a direct listing on the Nasdaq Global Market. The company's Chief Executive Officer is Matthew Mills, according to the filing.
The filing states that no public market for Med-X common stock currently exists and that the shares have a limited history of trading in private transactions. The company disclosed that recent private transaction prices "may have little or no relation to the opening public price" on Nasdaq or subsequent trading prices. The filing also notes that listing without a firm-commitment underwritten offering "is a novel method for commencing public trading" and that trading volume and price may be more volatile than in a traditional underwritten IPO.
According to the filing, on the day shares are initially listed, Nasdaq will begin accepting pre-opening buy and sell orders and will generate a "Current Reference Price" each second during a 10-minute "Display Only" period. Maxim Group LLC, in its capacity as financial advisor and also as a Registered Stockholder, will notify Nasdaq when shares are "ready to trade" and approve proceeding at the Current Reference Price, based primarily on considerations of volume, timing, and price. The filing states that neither Med-X nor the other Registered Stockholders will be involved in Nasdaq's price-setting mechanism.
What Was Disclosed
Med-X, Inc. filed its fifth amendment to an S-1 registration statement to register up to 16,248,842 post-split shares for resale via a Nasdaq direct listing, with Maxim Group LLC serving as financial advisor, and disclosed approximately $38,081,204 raised since inception through October 14, 2026.





Please wait processing your request...